|
| Particle | Loading capacity (%) | Loading efficiency (%) | Size (nm) | Administration route | In vitro/in vivo results | Ref. |
|
| NLCs (glyceryl tridecanoate, glyceryl tripalmitate, soy lecithin and Kolliphor HS15, and chitosan) | 3 | 99 | 50 | Oral | High stability in both acidic and neutral environments.
In vitro studies performed in THP-1-derived macrophages showed a decrease in inflammation and accumulation of cholesterol. | [27] |
|
| NLCs (phosphatidylcholine, Kolliphor HS15, and alpha-tocopherol acetate) | 10 | 96 | 108 | N/A | Increased EGCG stability. Enhanced accumulation inside macrophages and decrease in the production of MCP-1. | [28] |
|
| Phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, and phosphatidylinositol | N/A | N/A | 30–80 | Oral | Enhanced EGCG oral bioavailability in vivo and induction of α-secretase activity in neuronal cells in vitro. | [29] |
|
| NLCs (cetyl palmitate/Phospholipon 80, sesame oil, and Tween-80) | 2.7–3.6 | 99 | 126–167 | Topical | Photodegradation of EGCG under UVA radiation. | [30] |
|
| SLN (glycerol monostearate, stearic acid, soya lecithin, and Pluronic F68) | N/A | 67 | 157 | N/A | Enhanced stability in physiological fluids. Increased induction of cell death in breast cancer cells MDA-MB-231 and prostate cancer cells DU-145. | [31] |
|
| Cationic lipid nanocarriers (Softisan® 100, Poloxamer 188, glycerol, Lipoid® S75, and CTAB/DDAB) | N/A | N/A | ~150 | Ocular | Prolonged release of EGCG in biological medium. Permeation of rabbit cornea and sclera. | [32] |
|
